SULLENGER BRUCE A has a total of 13 patent applications. Its first patent ever was published in 2007. It filed its patents most often in United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are TGT LAB S A DE C V, RIBOMIC INC and SAH DINAH WEN-YEE.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 13 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Organic fine chemistry | |
#5 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Microorganisms | |
#3 | Medical preparations | |
#4 | Enzymes | |
#5 | Sugars | |
#6 | Peptides | |
#7 | Analysing materials | |
#8 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Sullenger Bruce A | 13 |
#2 | Rusconi Christopher P | 5 |
#3 | Mcnamara James | 3 |
#4 | Giangrande Paloma H | 2 |
#5 | Oney Sabah | 2 |
#6 | Bompiani Kristin | 1 |
#7 | Bompiani Kristin M | 1 |
#8 | Lam Tung Suet Ruby | 1 |
#9 | Leong Kam | 1 |
#10 | Frederiksen James | 1 |
Publication | Filing date | Title |
---|---|---|
US2014275226A1 | Method of controlling coagulation | |
US2012264815A1 | Reversible platelet inhibition | |
US2013210903A1 | Aptamers to glycoprotein VI | |
US2012183564A1 | Inhibition of endosomal toll-like receptor activation |